Jill Feldman: How Can Treatment Truly be Precise if We’re Only Seeing a Snapshot of the Cancer
Jill Feldman, Co-Founder of EGFR Resister, shared a post on LinkedIn:
“For years I have wondered, How can treatment truly be precise if we’re only seeing a snapshot of the cancer through a biopsy?
We talk about precision medicine, and yes, it has transformed how we treat lungcancer. But most people with lung cancer are diagnosed at an advanced stage and a biopsy is just a sliver of a highly heterogeneous tumor.
A recent study from Misty Shields lab on adenosquamous carcinoma (ASC), a rare and aggressive subtype of NSCLC, highlights this challenge. Over 37% of tumors have actionable targets, including KRAS G12C, METex14 and EGFR mutations. This raises big questions:
- How common is ACS really?
- Could tumor heterogeneity explain why some don’t respond to 1st line therapy?
- Are we missing key tumor characteristics that could impact treatment decisions?
Without a surgical specimen (whole tumor), are we missing the full story? We need better diagnostics, possibly including ctDNA/liquid biopsies that go beyond biomarkers to provide more detailed information about histology.”
Title: Brief Report: Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma
Authors: Tianhao Zhou, Olivia C. Terry, Katherine G. Minton, Lisa Poole, Stephen V. Liu, Balazs Halmos, Mya Tran, Nasser H. Hanna, Misty D. Shields
Read the Full Article.
More posts featuring Jill Feldman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023